Abstract
Objective: To test the compatibility of intravenous (IV) lactated Ringer’s injection (LR) with 94 injectable (IV) drugs during simulated Y-site administration. Methods: Ninety-four IV drugs were investigated for compatibility with LR (Baxter). Each sample was prepared in duplicate and performed at room temperature. Two observers performed visual evaluation independently immediately upon mixing and then 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours after admixture. Another observer performed a particle counting test on 1 of the 2 duplicates of each admixture that did not immediately show incompatibility and then after 4 hours by a light obscuration particle count test. Results: Of the 94 tested drugs, 86 were found to be compatible with LR. A total of 8 drugs were found to be physically incompatible. Of these incompatible drugs, 7 were directly identified visually and 1 was confirmed by the light obscuration particle count test. Conclusion: Lactated Ringer’s injection was physically compatible for 4 hours with 86 tested drugs during simulated Y-site administration. Eight drugs, ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, nitroglycerin, phenytoin, and propofol, were found to be incompatible and should not be administered with LR.
Keywords: lactated Ringer’s injection, compatibility, Y-injection site
Introduction
Lactated Ringer’s injection (LR) is a sterile, nonpyrogenic solution that may be used for intravenous (IV) irrigation, washing, and rinsing and also acts as a diluent for infusion of drugs. Lactated Ringer’s injection contains sodium chloride (Na+ 130 mEq/L), potassium chloride (K+ 4 mEq/L), calcium chloride (Ca+ 3 mEq/L), chloride (Cl− 109 mEq/L), and lactate (28 mEq/L) in water for injection. 1
Questions about drug compatibility are recurrent, and bringing up available information is an essential part of pharmacist assignment. Lactated Ringer’s injection is widely used in Sainte-Justine University Teaching Hospital, especially for patients receiving many other IV drugs by Y-site administration. Compatibility data about LR are scarce, and there is a need to evaluate the Y-site injection compatibility of LR with other IV drugs.
The purpose of this study was to determine Y-site injection compatibility of LR with 94 IV drugs using visual evaluation and light obscuration particle counting.
Methods
Lactated Ringer’s injection (lot W5I17C2) was provided by Baxter in 250 mL bags. A selection of 94 drugs was tested with LR. Details about the tested drugs and concentration are provided in Table 1. Tested IV drugs were reconstituted according to the manufacturer’s recommendation when required.
Table 1.
Drug name | Particle count test |
Visual |
|||||
---|---|---|---|---|---|---|---|
Concentration mg/mL (or as specified) | Manufacturer | Lot | Concentration mg/mL | Manufacturer | Lot | ||
1 | Acetazolamide sodium | 100 | Sterimax | 01000A15 01000B15A |
100 | SteriMax | 01000B11 |
2 | Acetylcysteine | 200 | Alveda Pharma | 14055056 | 200 | Alveda Pharma | 9075059 |
3 | Acyclovir sodium | 50 | PPC | 6008872 | 50 | PPC | 6002138 |
4 | Albumin, human (Alburex-25) | 250 | CSL Behring | 4309900011 | 250 | CSL Behring | 4309900011 |
5 | Amikacin sulfate | 250 | Sandoz | EZ9666 | 250 | Sandoz | BR9068 |
6 | Aminophylline | 25 | Hospira | 54-375-DK | 50 | Omega | OK472 |
7 | Amiodarone hydrochloride | 50 | Sandoz | FJ2260 | 50 | Sandoz | BR5023 |
8 | Amphotericin B liposomal | 4 | Astellas | 20160416074 | 4 | Bristol-Myers Squibb | 93070TB31 |
9 | Amphotericin B deoxycholate | 5 | Bristol-Myers Squibb | 51940TB24 | 5 | Bristol-Myers Squibb | 51940TB24 |
10 | Ampicillin sodium | 100 | Novopharm | FF7340 DS8980 |
100 | Novopharm | BP1879 |
11 | Atropine sulfate | 0.4 | Alveda Pharma | 50587 | 0.4 | Alveda Pharma | 434 |
12 | Azithromycin | 500 | Sterimax | 7602823 7602657 |
500 | Pfizer | Z065606 |
13 | Bretylium tosylate | 50 | Sandoz | EF9361 | 50 | Sandoz | AY2120 |
14 | Bupivacaine hydrochloride | 0.5% | Hospira | 48-198-DK | 20 mL | Hospira | 48-198-DK |
15 | Caffeine citrate | 10 | Sandoz | EM6977 | 10 | Sandoz | BR2092 |
16 | Calcium gluconate | 100 | Fresenius Kabi | 6010000 | 100 | PPC | 6001828 |
17 | Calcium chloride | 100 | Hospira | 52-393-DK 42-315-DK |
100 | Hospira | 89458DK |
18 | Caspofungin acetate | 5 | Merck | 2195750 | 5 | Merck | 2070040 |
19 | Cefazolin sodium | 100 | Hospira | 117F003 | 100 | Hospira | 117B004 |
20 | Cefotaxime | 100 | Sterimax | 4CS1513CA 4CS1512CA |
100 | Sanofi | 91846 |
21 | Cefoxitin | 100 | Novopharm | 0001D5 | 100 | Hospira | 123B002 |
22 | Ceftazidime | 100 | PPC | 105394C | 100 | PPC | 103573C |
23 | Ceftriaxone sodium | 100 | Hospira | H101HC4 H103HC4 |
100 | Hospira | 120B001 |
24 | Cefuroxime | 100 | Sterimax | 157012.1 | 100 | PPC | 8309 |
25 | Chlorpromazine hydrochloride | 25 | Sandoz | EF2262 DL5599 |
25 | Sandoz | AY5529 |
26 | Ciprofloxacin | 2 | Hospira | 50672 | 2 | Hospira | 4777201 |
27 | Clindamycin phosphate | 150 | Sandoz | FJ8765 | 150 | Sandoz | CS5861 |
28 | Cloxacillin sodium | 100 | Sterimax | 2CL1531CA | 100 | Novopharm | BP5356 |
29 | Cyclosporine | 50 | Novartis | S0076 S0070 |
50 | Novartis | S0065 |
30 | Dexamethasone sodium phosphate | 4 | Sandoz | FM3580 | 4 | Sandoz | F20120216057 |
31 | Dexmedetomidine hydrochloride | 0.1 | Hospira | 67-294-DK 63-198-DK |
0.100 | Hospira | 67-294-DK 63-198-DK |
32 | Dextrose 50% | 500 | Hospira | 50-239-DK | 500 | Hospira | 03399DK |
33 | Diazepam | 5 | Sandoz | 350085 429070 |
5 | Sandoz | BP9416 |
34 | Digoxin | 0.25 | Sandoz | FG7843 | 0.05 | Sandoz | BK4807 |
35 | Dimenhydrinate | 10 | Sandoz | FL9838 ES0313 |
10 | Sandoz | CB8792 |
36 | Diphenhydramine hydrochloride | 50 | Sandoz | 4K152 EJ5196 |
50 | Sandoz | CC6193 |
37 | Dobutamine hydrochloride | 12.5 | Hospira | 57-245-DK 61-123-DK |
12.5 | Sandoz | BT5348 |
38 | Dopamine hydrochloride | 3,2 | Baxter | P331496 | 3.2 | Baxter | 2BO846 |
39 | Enalaprilat | 1.25 | Sterimax | 143177.1 | 1.25 | Sandoz | CB8013 |
40 | Epinephrine hydrochloride | 1 | Erfa | F5E195 | 1 | Hospira | 107388E10 |
41 | Erythromycin lactobionate | 50 | Amdipharm | 44-906-TB-24 | 50 | Amdipharm | 88324TB26 |
42 | Esmolol hydrochloride | 10 | Baxter | 115376Z | 10 | Baxter | 071310Z |
43 | Fentanyl citrate | 0.050 | Sandoz | FU61144 | 0.050 | Sandoz | CD0281 |
44 | Fluconazole | 2 | Sandoz | EG3097 | 2 | Sandoz | BX9809 |
45 | Furosemide | 10 | Omega | 5J082 | 10 | Sandoz | BY8329 |
46 | Gentamicin sulfate | 10 | Sandoz | EZ8736 EW0069 |
40 | Sandoz | BU6761 |
47 | Granisetron hydrochloride | 1 | Omega | 4M838 | 1 | Omega | 4M838 |
48 | Haloperidol lactate | 5 | Sandoz | GB9093 FS6939 FM6054 |
5 | Sandoz | GB9093 FS6939 FM6054 |
49 | Heparin sodium | 1000 IU/mL | Sandoz | FU4871 | 1000 IU/mL | PPC | 6000130N |
50 | Hydralazine hydrochloride | 20 | Sterimax | PLNG1518 PLNK1438 PLNK1440 |
20 | Novartis | 00501B10 |
51 | Hydrocortisone sodium succinate | 50 | Novopharm | 0480514 4160115 |
50 | Novopharm | 9650310 |
52 | Hydromorphone hydrochloride | 10 | Sandoz | FA1043 | 10 | Sandoz | CC7651 |
53 | Hydroxyzine hydrochloride | 50 | Sandoz | EF1703 | N/A | N/A | N/A |
54 | Insulin regular (Humulin R) | 100 IU/mL | Lilly | C358890H C358890K |
100 IU/mL | Lilly | C001867D |
55 | Isoproterenol hydrochloride | 0.2 | Sandoz | FM8982 | 0.2 | Sandoz | BU3292 |
56 | Ketamine hydrochloride | 50 | Sandoz | FB4018 FK2313 |
50 | Sandoz | BX2917 |
57 | Labetalol hydrochloride | 5 | Sandoz | FD6396 | 5 | Sandoz | BW9642 |
58 | Lidocaine hydrochloride | 1% | Alveda Pharma | 15262021 | 1 | AstraZeneca | 10410 |
59 | Linezolid | 2 | Pfizer | 3770714 | 2 | Pfizer | 3770714 |
60 | Lorazepam | 4 | Hospira | 53275EV 52170EV |
4 | Sandoz | CZ3827 |
61 | Magnesium sulfate | 500 | Fresenius Kabi | 6010611 | 500 | PPC | 6101127 |
62 | Mannitol | 250 | Hospira | 60-222-DK | 250 | Hospira | 01485DK |
63 | Meropenem | 50 | Sterimax | 2694106 | 50 | AstraZeneca | JD947 |
64 | Methylprednisolone sodium succinate | 62.5 | Novopharm | 6000215 4450915 |
62.5 | Pfizer | G00030 |
65 | Metoclopramide hydrochloride | 5 | Sandoz | EM2979 EL7926 EL4390 EG3207 FG3415 |
5 | Sandoz | BY4533 |
66 | Metronidazole | 5 | Hospira | 58-011-JT | 5 | Hospira | 7811853 |
67 | Midazolam hydrochloride | 5 | Fresenius Kabi | 6009861 | 5 | PPC | CB8867 |
68 | Milrinone lactate | 1 | Sandoz | FH8172 | 1 | Sandoz | CB2379 |
69 | Morphine sulfate | 50 | Sandoz | FC1902 | 50 | Sandoz | BR8368 |
70 | Multivitamins (Multi-12/K1 pediatric) | Sandoz | FL5796 (vial 1) FL6371 (vial 2) |
Sandoz | CY0799 et CY0797 |
||
71 | Multivitamins (Multi-12) | Sandoz | FL5795 (vial 1) FK1211 (vial 2) |
Sandoz | CG5111 | ||
72 | Naloxone hydrochloride | 0.4 | Alveda Pharma | 30209 30522 |
0.4 | Sandoz | BL1147 |
73 | Nicardipine hydrochloride | 0.2 | Baxter | NC096925 | 0.2 | Baxter | NC096925 |
74 | Nitroglycerin | 5 | Omega | 5GO44 5D948 |
5 | Omega | 1K775 |
75 | Norepinephrine bitartrate | 1 | Sandoz | FD2438 | 1 | Sandoz | BU3181 |
76 | Octreotide acetate | 0.500 | Omega | 5F008 5J086 |
0.500 | Omega | S0013 |
77 | Oxytocin | 10 IU/mL | Hospira | 521388E01 | 10 IU/mL | Hospira | 054528E01 |
78 | Penicillin G sodium | 500 000 IU/mL | Fresenius Kabi | 303246 | 100 000 IU/mL | Novopharm | CG7189 |
79 | Phenytoin sodium | 50 | Sterimax | 152079.1 | 50 | Sandoz | CJ8539 |
80 | Piperacillin sodium | 200 | Hospira | 1P301MC3 | 200 | Mayne Pharma | 1P301MC1 |
81 | Piperacillin sodium / Tazobactam | 200 | Sandoz | 20160428083 | 200 | Sandoz | BW5243 |
82 | Potassium chloride | 2 mEq/mL | Hospira | 50-151-DK | 2 mEq/mL | Hospira | 92180DK |
83 | Potassium phosphate | 3 mmol/mL | Sandoz | 6109697 | 3 mmol/mL | Sandoz | BW8396 |
84 | Propofol | 10 | Pharmascience | A050374 | 10 | Novopharm | R10167B |
85 | Ranitidine hydrochloride | 25 | Sandoz | F59330 FW1356 |
25 | GlaxoSmithKline | C566822 |
86 | Rocuronium bromide | 10 | Sandoz | FS6942 FM5396 |
10 | Hospira | 12008DK |
87 | Salbutamol | 1 | GlaxoSmithKline | V972 | 1 | GlaxoSmithKline | L061 |
88 | Sodium bicarbonate | 1 mEq/mL | Hospira | 54-178-EV | 1 mEq/mL | Abbott | 11138DK |
89 | Sodium nitroprusside | 25 | Hospira | 531303A | 25 | Omega | 1K775 |
90 | Tobramycin sulfate | 40 | Sandoz | 6009024 | 40 | Sandoz | C152865 |
91 | Trimethoprim / Sulfamethoxazole | 16/80 | GlaxoSmithKline | 20160422036 | 16/80 | GlaxoSmithKline | 1E531 |
92 | Vancomycin hydrochloride | 50 | Sandoz | FF5576 FW3816 |
50 | Hospira | 096588E02 |
93 | Verapamil hydrochloride | 2.5 | Sandoz | FM1440 | 2.5 | Sandoz | CM0627 |
94 | Voriconazole | 10 | Sandoz | FY0203 | 10 | Sandoz | FY0203 |
Ninety-four drugs were tested in 1:1 admixture with LR in testing glass tubes at room temperature and under normal room light. Each drug available in a breakable glass ampoule was passed through a 5-µm filter as it was introduced into the testing glass tube.
Step 1: Visual evaluations were performed independently by 2 observers in accordance with the established procedure previously reported several times.2-8 Visual simulated Y-site injection evaluation was accomplished by the 2 observers by mixing 1 mL of LR with 1 mL of the tested drug in glass tube and then switching the order of drug mixing for the second observation. Each admixture was visually observed immediately upon mixing and then at specified time points: 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours. Visual compatibility was defined as the absence of any color change or visible particle matter, gas bubble, substantial haze, or precipitate by a naked eye.
Step 2: Another second observer performed the light obscuration particle count test using the LS-20 Liquid Particle Counter (Lighthouse Worldwide Solutions, Medford, OR). At the beginning of the experiment, the particle count test was controlled by a standardized solution (Pharm-Trol Particle Count Control solution; Thermo Scientific, Saint-Laurent, QC, Canada, lot 44035) with a specific concentration of 15 µm particles. This allowed us to ascertain that the accuracy of the particle counter is in agreement with the United States Pharmacopeia (USP) Reference Standard for the duration of the observations. Furthermore, on each day of observation, a control solution made of 10 mL of LR and 10 mL of sterile water for injection passed both the visual test and the particle count test immediately upon mixing and after 4 hours. Then each admixture was tested in sterile plastic syringes by mixing 10 mL of LR with 10 mL of the tested drug. In the absence of visual incompatibility, the particle content of the first admixtures was immediately analyzed and that of the second was quantified by a final particle count test at 4 hours. Admixtures that were visually incompatible were immediately discarded without particle count test evaluation. Drug admixtures were considered compatible if the average number of particles did not exceed USP <788> Test 1.B guidelines. 9 In this study, volumes are less than 100 mL, and the limit allowed for particulate matter does not exceed 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Thus, with a container volume of 20 mL, 5 mL per test, the average number of particles equal to or greater than 10 µm does not exceed 300 particles and no more than 30 particles equal to or greater than 25 µm to be considered compatible. Each measure was in triplicate, 3 times 5 mL, with 4 mL as a prime.
Results
A total of 94 admixtures were visually inspected in step 1, and 77 of them demonstrated no evidence of visual incompatibility immediately and throughout the 4-hour period. Seventeen drugs were described as being possibly or definitively incompatible with LR when inspected visually by 2 different observers. Table 2 illustrates the details associated with the 17 admixtures that could possibly be visually incompatible.
Table 2.
Drug name | Notes | |
---|---|---|
1 | Amiodarone | Uncertain |
2 | Caspofungin | Uncertain |
3 | Ciprofloxacin | Incompatible |
4 | Clindamycin | Uncertain |
5 | Cyclosporine | Precipitate |
6 | Diazepam | Immediate precipitate |
7 | Insulin (human regular) (Humulin R) |
Uncertain |
8 | Ketamine | Incompatible |
9 | Lorazepam | Incompatible |
10 | Methylprednisolone | Uncertain |
11 | Multivitamins (adult) (Multi-12) |
Uncertain |
12 | Multivitamins (pediatric) (Multi-12/K1 pediatric) |
Uncertain |
13 | Nitroglycerin | Uncertain |
14 | Penicillin G | Uncertain |
15 | Phenytoin | Incompatible |
16 | Propofol | Precipitate |
17 | Verapamil | Uncertain |
In step 2, just before the light obscuration particle count test, 7 admixtures showed precipitation (ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, phenytoin, propofol) and were discarded without particle count test evaluation because there is evidence of incompatibility. All the other 10 admixtures that were suspected to be visually incompatible and did not clearly precipitate were analyzed by the particle count test, including all the other 77 certain results by visual inspection, to determine whether they were really compatible or not. For 86 drugs, measurement of the number of particles ≥25 and ≥10 µm was within specification limit immediately upon admixture and after 4 hours. Only for 1 drug, nitroglycerin, particle counting and sizing confirmed the incompatibility suspected (Table 3).
Table 3.
Drug name | Notes | |
---|---|---|
1 | Nitroglycerin | >30 × 25 µm particles/mL at T = 0 |
In summary, all the incompatible drugs are listed in Table 4, with the corresponding reason.
Table 4.
Drug name | Incompatibility reason | |
---|---|---|
1 | Ciprofloxacin | Directly by visual inspection |
2 | Cyclosporine | Directly by visual inspection |
3 | Diazepam | Directly by visual inspection |
4 | Ketamine | Directly by visual inspection |
5 | Lorazepam | Directly by visual inspection |
6 | Nitroglycerin | Especially with light obscuration particle count test |
7 | Phenytoin | Directly by visual inspection |
8 | Propofol | Directly by visual inspection |
Discussion
Lactated Ringer’s injection is widely used as a drug diluent. Until now, no study has evaluated specifically the compatibility of LR with drugs used in clinical practice. This study tested the compatibility of LR with 94 injectable drugs.
The simulated Y-site injection model used in this study is based on the model described by Allen et al in 1977. They established that when mixing 2 solutions in a Y-administration set, the concentration ratio will be 1:1. 10 As admitted, if 2 drugs are compatible at high concentration, they will also probably be compatible at lower concentrations. 11 This hypothesis reflects the condition in Y-site administration that is used by nurses during drug administration.
Results by visual control show that 10 drugs are possibly incompatible with LR, whereas 7 are incompatible after visual test. Visual control can only detect particles greater than 50 µm, whereas the light obscuration particle count test assesses particle within the range of 1 to 50 µm and permits to comply with USP <788> Test 1.B. 9 This could explain the difference seen between the results of the 2 testing methods. This is why the results obtained with the particle count test are more reliable than those obtained by visual control. However, when admixture leads to an obvious precipitation, the particle count test is not processed, thus becoming useless.
Precipitate formation occurred when propofol was mixed with LR. Because propofol is an opaque white emulsion, particle count test could not be performed due to its dense turbidity. Propofol would require an alternative approach to physical compatibility other than particle count test evaluation.
Concerning cyclosporine and nitroglycerin, the present results are not congruent with published data.12-14 These 2 drugs are listed as compatible with LR in some visual studies12,13 where physical compatibility was evaluated only by the absence of changes in measured haze or turbidity, particulates, or color found. The light obscuration particle count test was required to detect an incompatibility like in this study. Cyclosporine needs to be diluted to a concentration of 5 mg/mL or less using sterile water before testing with light obscuration particle count test because the 50 mg/mL solution is too viscous for particle count test analysis and even more diluted for clinical practice.2,14 The dilution factor used could explain the difference between other data because a drug could be incompatible at high concentration but be compatible, almost for 4 hours, after being diluted. Nitroglycerin incompatibility with LR could be detected by the light obscuration particle count test, depending on techniques used by other authors, which could explain the conflicting result.
Surprisingly, compatibility results were found with drugs such as ceftriaxone, amphotericin B (Fungizone), and piperacillin sodium/tazobactam that are supposed to be incompatible according to published data.14-18 Several factors may explain these differences as contact time, methods, concentrations, diluents, manufacturers, and excipients. Lack of recent studies for these drugs makes the result obtained with a modern particle counting test confident to be trusted.
All other results of this study are consistent with the results of previous compatibility studies and demonstrate the value of the light obscuration particle count test to assess compatibility between 2 drugs and complete visual inspection, eliminating hazardous results. Lactated Ringer’s injection and each other drug were tested at 1 concentration, and it is possible that the incompatible combinations might be compatible when mixed at lower concentrations.
Conclusion
Lactated Ringer’s injection was compatible with 86 of the drugs tested and was found to be directly incompatible by naked eye with ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, phenytoin, and propofol and additionally by light obscuration particle count test with nitroglycerin. The light obscuration particle count test to assess compatibility between 2 drugs completes visual inspection, eliminating hazardous results.
Footnotes
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.
ORCID iD: Jean-Marc Forest https://orcid.org/0000-0001-8451-5471
References
- 1. National Center for Biotechnology Information (US). PubChem Compound Database; CID = 56841910 (Ringer’s lactate solution). Bethesda, MD: National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/56841910#section=Top. Accessed October 5, 2016. [Google Scholar]
- 2. Sullivan T, Forest J-M, Leclair G. Compatibility of cloxacillin sodium with selected intravenous drugs during simulated Y-site administration. Hosp Pharm. 2015;50(3):214-220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Ferreira E, Forest J-M, Hildgen P. Compatibilité du dimenhydrinate injectable pour l’administration en Y. Pharmactuel. 2004;37(1):17-20. [Google Scholar]
- 4. Péré H, Chassé V, Forest J-M. Compatibilité du pantoprazole injectable lors d’administration en Y. Pharmactuel. 2004;37:193-196. [Google Scholar]
- 5. Pelletier Forest ÉJ-M, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel. 2006;39:71-75. [Google Scholar]
- 6. Pelletier E, Forest J, Hildgen P. Compatibilité des mélanges de morphine et de kétamine ou d’hydromorphone et de kétamine injectables lors de leur administration en dérivé avec d’autres médicaments usuels. Pharmactuel. 2007;40(2):23-27. [Google Scholar]
- 7. Tollec S, Touzin K, Pelletier E, Forest J-M. Évaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel. 2013;46(1):6-21. [Google Scholar]
- 8. Legris M-E, Lavoie A, Forest J-M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel. 2015;47(3):67-172. [Google Scholar]
- 9. The United States Pharmacopeia. Particulate matter in injections. Rockville, MD: United States Pharmacopeia; 2019. [Google Scholar]
- 10. Allen LV, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm Sept. 1977;34(9):93943. [PubMed] [Google Scholar]
- 11. Trissel LA. Handbook on Injectable Drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2003. [Google Scholar]
- 12. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—cyclosporin compatibility detail. http://www.micromedexsolutions.com. Accessed October 18, 2018.
- 13. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—nitroglycerin compatibility detail. http://www.micromedexsolutions.com. Accessed October 19, 2018.
- 14. Trissel LA, Leissing NC. Trissel’s Tables of Physical Compatibility. Lake Forest, IL: Multimatrix, Inc; 1996. [Google Scholar]
- 15. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—ceftriaxone compatibility detail. http://www.micromedexsolutions.com. Accessed October 21, 2018.
- 16. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral compatibility): Lactated Ringer’s injection—phenytoin compatibility detail. http://www.micromedexsolutions.com. Accessed October 24, 2018.
- 17. Truven Health Analytic’s: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—fungizone compatibility detail. http://www.micromedexsolutions.com. Accessed October 21, 2018.
- 18. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral compatibility): Lactated Ringer’s injection—Sulfamethoxazole-trimethoprim compatibility detail. http://www.micromedexsolutions.com. Accessed November 11, 2018.